Your search for Dapagliflozin returned 105 results

Latest findings are from a post hoc meta-analysis of pooled data from the DAPA-HF and DELIVER trials.

Reduction seen in rate of admissions due to cardiac disorders, renal and urinary disorders, metabolism and nutrition disorders, neoplasms

Primary end point similarly reduced for men and women with dapagliflozin; no differences in secondary outcomes, safety events

The findings were consistent across key subgroups examined (eg, LVEF<60%, diabetes)

Understanding clinical characteristics associated with a decline in eGFR can help guide optimal use of SGLT2 inhibitors in clinical practice, according to investigators.

Investigators report findings from a secondary analysis of the DARE-19 trial, which compared dapagliflozin with placebo in patients hospitalized with COVID-19.

The placebo-controlled, event-driven DELIVER study included 6263 patients.

Effects of dapagliflozin on primary and secondary outcomes consistent for those with eGFR <60 and ≥60 mL/min per 1.73 m²

Study findings suggest the nephroprotective effects of both drug classes are complementary.

Risk reduced for worsening heart failure or cardiovascular death, regardless of frailty index class